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Abstract
Background Idiopathic pulmonary fibrosis (IPF) is a
debilitating condition with significant morbidity and poor
survival. Since 2010, there has been increased activity in
the development of treatments that aim to delay progres-
sion of the disease.
Objective Our study involves a comprehensive review of
the literature for evidence on health-related quality of life
(HRQoL), healthcare resource use (HCRU) and costs, and
an assessment of the burden of illness of the condition.
Methods We carried out a systematic literature review
(SLR) to identify economic evaluations and HRQoL
studies. We searched EMBASE, MEDLINE and MED-
LINE In Process for relevant studies from database origins
to April 2017. Alongside the presentation of the study
characteristics and the available evidence, we carried out a
qualitative comparison using reference population esti-
mates for HRQoL and national health expenditure for
costs.
Results Our search identified a total of 3241 records. After
removing duplicates and not relevant articles, we analysed
124 publications referring to 88 studies published between
2000 and 2017. Sixty studies were HRQoL and 28 were
studies on costs or HCRU. We observed an exponential
growth of publications in the last 3–5 years, with the
majority of the studies conducted in Europe and North
America. Among the HRQoL studies, and despite regional
differences, there was some agreement between estimates
on the absolute and relative level of HRQoL for patients
with IPF compared with the general population. Regarding
costs, after adjustments for the cost years and currency, the
suggested annual per capita cost of patients with IPF in
North America was estimated around US$20,000, 2.5–3.5
times higher than the national healthcare expenditure.
Additionally, studies that analysed patients with IPF
alongside a matched control cohort suggested a significant
increase in resource use and cost.
Conclusion The reviewed evidence indicates that IPF has
considerable impact on HRQoL, relative to the general
population levels. Furthermore, in studies of cost and
resource use, most estimates of the burden were consistent
in suggesting an excess cost for patients with IPF compared
with a control cohort or the national health expenditure.
This confirms IPF as a growing threat for public health
worldwide, with considerable impact to the patients and
healthcare providers.Electronic supplementary material The online version of this
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Key Points
Acquiring knowledge on the overall burden of
idiopathic pulmonary fibrosis (IPF) is essential for
stakeholders planning resource allocation across
many conditions. This study provides an overview of
the evidence on health-related quality of life
(HRQoL) and costs in IPF.
Several studies showed that IPF has a considerable
impact on patients’ HRQoL, including physical and
social components, in comparison with the general
population.
Compared with the national health expenditure or
control-matched patient cohorts, IPF was associated
with an excess healthcare cost.
Our findings confirm IPF as a growing threat for
public health worldwide, with considerable impact to
the patients and healthcare providers.
1 Introduction
Idiopathic pulmonary fibrosis (IPF) is a specific form of
chronic, progressive fibrosing interstitial pneumonia of
unknownaetiology associatedwith significantmorbidity and
poor survival [1]. The symptoms include dyspnoea, dry
cough, tiredness, aching of muscles and joints, unintended
weight loss and finger clubbing [1]. The progression of the
disease varies significantly between patients and depends on
many clinical and external factors [2]. Overall, individuals
with IPF have similar life expectancy to thosewith non-small
cell lung cancer, with reported estimates of median survival
being 50% at 3 years and 20% at 5 years post-diagnosis
[1, 3–5]. The estimates of incidence and prevalence of IPF
vary depending on the definition used, the study design, and
the underlying population characteristics (such as age, gen-
der, geographic location, etc.) [3, 6]. In general, studies agree
that the condition is more common in men and in older
people. In Europe, the British Thoracic Society estimates
that the prevalence is around 50 per 100,000 population, with
the highest rates in Northern Ireland, North West England,
Scotland and Wales [7]. This is considerably higher than
older estimates from other parts of Europe such as Norway
(19.7–23.9/100,000) [8] and Belgium (1.25/100,000) [9]. In
North America, two US studies placed the prevalence esti-
mates between 42.7 [10] and 63 [11] patients per 100,000
population (using the broad definition); while a more recent
Canadian study reported the prevalence to be as high as
115/100,000 (broad definition) [12]. Similarly, in Japan
studies suggested prevalence estimates from 2.9/100,000 in
2005 [13] to 10/100,000 population in 2007 [4]. It follows
that, although IPF is still treated as a rare condition in many
countries, the evolution of diagnostic methods and greater
physician awareness around the disease and an aging popu-
lation may be leading to an increase in the prevalence and
incidence rates over time [6, 14, 15].
There is also considerable activity in the development of
treatments for the condition. Before 2010 there was no
licensed pharmacological treatment for this devastating
disease [1]. In 2008, pirfenidone was approved in Japan
and in 2011 by the European Medicines Agency (EMA). In
2014 the US Food and Drug Administration (FDA)
approved both pirfenidone and nintedanib, with EMA also
confirming approval for nintedanib soon after [16–18].1
Despite the recent termination of the clinical trial pro-
grammes for tralokinumab [19] and simtuzumab [20], a
number of new agents are being tested in experimental
trials for the treatment of IPF (SAR156597 [21], lebrik-
izumab [22], FG-3019 [23], PRM-151 [24] and others).
For healthcare providers, who often have to make dif-
ficult decisions about resource allocation across many
conditions, in-depth knowledge of the overall burden of the
disease is essential. Our study involves a comprehensive
review of the literature for evidence on health-related
quality of life (HRQoL) and costs. It also attempts a
qualitative comparison with estimates of HRQoL for the
general population and national healthcare expenditure to
illustrate the burden of illness of IPF.
2 Methods
The study followed the PRISMA (Preferred Reporting
Items for Systematic review and Meta-Analysis)
guidelines.
2.1 Search Strategy
Two separate systematic reviewswere conducted for economic
evaluations andHRQoLevidence.Using theOvid interface, the
databases EMBASE, MEDLINE and MEDLINE In Process
were searched for relevant studies. Search terms included dis-
ease-specific, economic or cost, and HRQoL keywords such as
‘idiopathic AND pulmonary AND fibrosis’, ‘fibrosing alve-
olitis’, ‘interstitial pneumonia’, ‘costs and cost analysis’ and
‘health care costs’, ‘HRQoL’, ‘EQ-5D’.2
1 Nintedanib was also approved in Japan, Canada, Switzerland and
many other countries.
2 For details on the search strings see the electronic supplementary
material.
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A review of HRQoL was conducted in August 2014 for
the development of an economic analysis [25]. All the
relevant records from the 2014 review were retrieved and
the searches were updated from January 2014 to April
2017.
The economic data search was conducted from database
origins to April 2017.
All references were imported into Endnote and duplicate
citations were removed.
2.2 Study Selection
A review protocol with inclusion and exclusion criteria was
developed at the outset of the study. The inclusion criteria
were for adult patients with IPF without any restrictions on
the therapy received. Other criteria included the reporting
of unit costs, resource use, and HRQoL measures. To
increase homogeneity in the study population characteris-
tics, we excluded records that reported costs of diagnosis of
interstitial lung disease (ILD).
The protocol was modified during the study to exclude
abstract-only records published before 2015 (most often
conference proceedings). Those records rarely provided
sufficient information on methods and results that could be
useful in our study and in general lack the scrutiny of full
journal articles. Nevertheless, more recent records (post-
2014) were included in our study, as we assumed that at the
time of our search they were in development to a
manuscript.
Screening of records was conducted in two phases (title/
abstract and full-text). One experienced reviewer covered
each dataset of records for economic evaluations and
HRQoL evidence (EW and KV, respectively). A quarter of
the records were screened independently by a second
reviewer (AD, LC). If the decision for inclusion or exclu-
sion was different in more than 10%, the full set of records
were reviewed again. Because of a[10% disagreement in
the HRQoL dataset, all records were screened in a double-
blind manner. The bibliography of another literature review
study [26] was used to validate our findings.
2.3 Data Extraction and Analysis
Key pieces of information from the selected studies were
extracted in piloted tables by three experienced researchers
(EW, KV, LC). A quality check of the data extraction was
done by AD. The tables were different for HRQoL and
economic evidence. Given the heterogeneity of the eco-
nomic evidence, we later separated studies that reported
healthcare resource use or costs from economic evaluations
(cost-effectiveness or budget impact analyses).
3 Results
The database searches identified a total of 3241 records.
After removing duplicate records, 2496 abstracts were
screened against the eligibility criteria. Twelve additional
records were identified via bibliography searches.
A total of 127 publications were included in the quali-
tative analysis, referring to 66 HRQoL and 28 economic
studies. The economic studies were further categorised,
with 18 reporting resource use or costs and 10 reporting on
cost-effectiveness or budget impact analyses. The overall
breakdown of the screening process in the reviews is pre-
sented in a PRISMA flow diagram (Fig. 1).
The studies on HRQoL increased over time with almost
half conducted and published in the 3.5 years between
2014 and 2017 (see Fig. 2).3 We did not identify any cost
or economic evaluation studies conducted before 2010,
while more than half of the cost studies were published in
the last 3 years.
In terms of geographic regions, the majority of the
studies were conducted in Europe and North America
(USA and Canada) (Fig. 3). The most studied country was
the USA with 13 HRQoL [27–40] and eight economic
evidence publications [41–48]. From low income and
lower middle income countries (using the World Bank
definition [49]) we identified two studies on HRQoL from
Egypt [50, 51] and one from India [52]. From east Asia the
predominant country was Japan with nine HRQoL studies
[53–61]; one study was identified from China (HRQoL)
[62] and one from Korea (costs) [63]. In the HRQoL
dataset, for a number of studies we did not identify a clear
country of origin [64–67].
3.1 Health-Related Quality of Life Evidence
A total of 66 studies were identified (33 in the pre-2014
analysis and 33 post-2014) with HRQoL data in IPF pop-
ulations. Details of the study location, the population, the
HRQoL assessment tools used, and the time points, as well
as the sources of funding, are presented in Table 1.
In all studies, apart from Jastrzebski et al. [69], the
population mean age was over 50 years old, with the
average age around 65–70 years old. The study populations
were predominantly male with the exception of three
studies reporting a higher proportion of female [32, 51] or
an equal male/female ratio [30].
The majority of the studies used the disease-specific
HRQoL instrument, St. George’s Respiratory Question-
naire (SGRQ), reported in 41 studies. Most of the studies
measuring HRQoL with the SGRQ reported results for the
3 Note that searches were conducted in April of 2017; hence, only
one quarter of the last year contributed to our results.
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three categories: symptoms, impact and activity; in addi-
tion to the total score. Despite the development and vali-
dation of an IPF-specific version of the SGRQ, the SGRQ-I
[70], most investigators, apart from Gaunaurd et al.
[28, 71, 72], continue to use the original version.
In addition, six studies reported other disease-specific
HRQoL scores such as A Tool to Assess Quality of life in
IPF (ATAQ-IPF) [37] or the King’s Brief Interstitial Lung
Disease (K-BILD) [73]. The 36-Item Short Form Survey
(SF-36) was reported in 26 studies, the EuroQol 5-level
questionnaire (EQ-5D) in four studies [39, 40, 67, 74, 75],
the SF-12 in two studies and one Canadian study reported
Health Utilities Index Mark 2 (HUI2) scores. One study
was assessing the mapping of SGRQ data to EQ-5D [76]
and another study provided a mapping algorithm from
SGRQ data to SF-36 [77]. Further, EQ-5D estimates from
phase III trials with nintedanib in IPF (INPULSIS I and
II) were available from an economic evaluation identified
during the economic data search [25].
Fig. 1 PRISMA flowchart. HRQL health-related quality of life, HCRU healthcare resource use
Fig. 2 Summary of studies by
publication date. HRQL health-
related quality of life
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Table 2 reports on a subsection of the studies we found
that included HRQoL values based on multi-attribute
preference-based measures (EQ-5D and HUI2). We
obtained population reference scores for EQ VAS and EQ-
5D from a survey conducted across 24 countries [78]. The
survey presented scores by age and we selected the 65–74-
year age category as the most representative of the IPF
studies that we are using in our comparison. To obtain a
reference for HUI2 scores, we looked at the US National
Health Measurement Study (NHMS) using the scores for
ages 65–74 years [79].
Overall, the HRQoL was found to be lower for patients
with IPF compared with the general population (Fig. 4).
In the German registry, INSIGHTS-IPF, the EQ VAS of
the patients with IPF, was about 9 points lower on the
scale compared with the population reference data
[80–84]. The difference in the EQ-5D index score was
0.223 lower than the reference. The incremental differ-
ence between patients with IPF and the population ref-
erence is smaller in the US study STEP-IPF: around 7.5
points on EQ VAS and around 0.1 on EQ-5D index scores
[67]. Furthermore, in the study by Rinciog et al. [25], the
reported difference in EQ-5D index score ranges from a
category with relatively good lung function (forced vital
capacity [FVC][90% predicted: 0.84) to very poor
(FVC\50% predicted: 0.67).
On the HUI2 instrument, the IPF population utility
estimates were substantially lower than those measured on
the EQ-5D scale, both for the first year with IPF (0.585)
and the fourth year (0.432) [12]. However, some of the
difference with the reference scores may be attributed to
country variations (US data were used for HUI2 reference).
Regarding other multi-attribute instruments, eight stud-
ies reported the average score or the mental and physical
component scores (MCS and PCS) of SF-36
[27, 29, 34, 35, 39, 40, 67, 69, 85, 86]. One study reported
an SF-36 score of 32± 11.4 for severe IPF (defined as
diffusing capacity of the lungs for carbon monoxide
[DLCO]\30%) and 59.1± 17.8 for patients with mild-to-
moderate IPF (DLCO[30%) [27]. King et al. reported the
SF-36 score of 45.7 for placebo and 45.2 for people treated
with bonsentan [86]. At baseline, SF-36 PCS scores varied
between 26.0± 8.0 [85] to 40.6± 9.3 [40], with an average
value of 35 and SF-36 MCS ranging from 42 [69] to
55.7± 7.4 [40] with an average value of 48. The 17
remaining studies detailed the SF-36 results by question-
naire items (physical functioning, social functioning,
mental health, role limitations due to physical problems,
role limitations due to emotional problems, vitality, bodily
pain, and general health perceptions).
3.2 Cost and Healthcare Resource Use Evidence
A total of 18 studies were identified with HCRU and cost
evidence (Table 3). The majority were retrospective cohort
analyses of claims data. Three studies were based on a
synthesis of HCRU and national costs or tariffs [87–89].
One study was based on randomised clinical trial evidence
[90] and one study was based on clinical expert opinion
[91].
The most common reported resource or cost was hos-
pitalisation (all-cause and/or respiratory-related), emer-
gency room visits, and acute IPF exacerbation events. The
majority of the studies [14] reported costs alongside
Fig. 3 Regional distribution of
identified studies. HRQL health-
related quality of life. Asterisk
indicates the location was not
clearly reported in the study
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resource use. Four studies reported only HCRU data
[47, 90, 92, 93].
Eight of the studies that reported costs presented esti-
mated total cost per capita [41, 42, 44, 63, 88, 91, 94, 95]
(see Table 4). In three US studies the annual total cost of
IPF was estimated at around US$20,000 per patient
[41, 42, 44]. Controlled for the year the studies were
conducted, this estimate was around three times the
national per capita health expenditure [96].
In 2012, Collard et al. [42] also presented the total costs
per person-year for patients with IPF and a matched control
cohort (US$26,378 vs US$14,254). In a different study,
published a few years later (2015), Collard et al. [41]
showed similar estimates of the difference between patients
with IPF and controls (US$20,887 vs US$8932).
In a study from Canada [94], the annual cost per patient
with IPF was lower than the US studies [41, 42, 44].
However, in relative terms the study estimated a[3 times
greater cost when comparing with the per capita Canadian
national heath expenditure.
The annual total cost per patient in Korea [63] was
estimated to be\10% of the cost presented in the Ameri-
can studies [41, 42, 44]. In the same study, the contribution
of hospital admission costs to the total healthcare cost was
found to be 86.7–88.8%. We also found great disparity in
the estimates of the two studies from Spain [91, 97].
An abstract by Hill et al. [88] conducted a bottom-up
cost analysis of service provision costs (excluding treat-
ments) in England (NHS) in 2014. They estimated that the
actual cost of services was over 40% of the tariff reim-
bursed by the NHS for each patient with IPF.
From the studies that reported resource use, Wu et al.
[93] presented evidence of HCRU in US patients with IPF
compared with a matching control cohort (1:3 matching
ratio). They found that the mean differences between
patients with IPF and control were more pronounced in
outpatient hospital visits (7.5 vs 2.7), physician office visits
(16 vs 7.8), and oxygen therapies (7.8 vs 0.6). After a
multivariate adjustment, the magnitude of the difference
was reduced for the outpatient hospital, physician and
emergency room visit statistics. Nevertheless, it remained
significantly higher for patients with IPF versus non-IPF.
Only five studies reported treatment costs
[42, 44, 63, 89, 91]. In Kim et al., treatment costs were
between 8–10% of the total costs [63]. However, it was not
reported which treatment was considered. In the remaining
studies, treatments included corticosteroids, oxygen ther-
apy, azathioprine, cyclophosphamide, N-acetylcysteine
(NAC), pulmonary rehabilitation therapy and lung trans-
plantation. Of the new treatments, in Morell et al. it was
reported that pirfenidone was offered to patients with IPF
on compassionate grounds; it is unclear whether the cost of
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Table 2 HRQoL burden of IPF
Study Patient characteristics HRQoL multi-
attribute
measurement tool
IPF utility score Population
reference dataa
INSIGHTS-
IPF [80–84]
N = 572 patients; 77.1% males; mean age 69.4± 8.8 years;
disease 2.1± 3.3 years; FVC % predicted 72.6± 19.2;
DLCO % predicted 36.1± 17.1
EQ VAS 59.8± 19.8 Germany, age
65–74 years:
68.6
EQ-5D-5L 0.668± 0.214b Germany, age
65–74 years:
0.891
BUILD-1
[77, 86, 134]
N = 407 patients; 73% males; mean age 65.12± 8.93;
disease\3 years; FVC % predicted 66.97± 12.17; DLCO %
predicted 40.98± 10.08
EQ VAS Placebo:
69.5± 19.4
Bosentan:
70.4± 18.7
N/A
(international
study)
EQ-5D Placebo:
0.718± 0.242
Bosentan:
0.758± 0.185
N/A
(international
study)
STEP-IPF [67] Placebo N = 91 patients; 84% males; mean age 68.20± 9.25;
disease 1.87± 1.93 years, FVC % predicted 58.73± 14.12;
DLCO % predicted 26.73± 6.16
EQ VAS Baseline:
67.66± 16.98
Change at
12 weeks: - 1.81
(- 5.34 to 1.73)
USA, age
65–74 years:
75.1
EQ-5D-5L Baseline:
0.74± 0.19
Change at
12 weeks: - 0.03
(- 0.08 to 0.01)b
USA, age
65–74 years:
0.817
Sildenafil N = 89 patients; 86% males; mean age
69.76± 8.71; disease 2.03± 1.94 years, FVC % predicted
54.89± 14.00; DLCO % predicted 25.81± 6.03
EQ VAS Baseline:
66.49± 17.45
Change at
12 weeks: 0.48
(- 3.10 to 4.06)
USA, age
65–74 years:
75.1
EQ-5D-5L Baseline:
0.71± 0.24
Change at
12 weeks: - 0.01
(- 0.06 to 0.03)b
USA, age
65–74 years:
0.817
INPULSIS I
and II [25]
Placebo N = 423 patients; 79% males; mean age
67± 7.9 years; disease 1.57± 1.31 years; FVC % predicted
79.27± 18.22
Nintedanib N = 638 patients; 79.5% males; mean age
66.6± 8.1 years; disease 1.65± 1.36 years; FVC %
predicted 79.74± 17.57
Both arms were pooled for this analysis
EQ-5D-3L FVCC 90%
0.84± 0.18
FVC 80–89.9%
0.81± 0.21
FVC 70–79.9%
0.78± 0.22
FVC 60–69.9%
0.77± 0.24
FVC 50–59.9%
0.74± 0.23
FVC 40–49.9%
0.66± 0.26
N/A
(international
study)
Idiopathic Pulmonary Fibrosis Burden of Illness
pirfenidone contributed to the treatment costs in that study
[91].
3.3 Economic Evaluations
Ten studies were identified assessing the cost effectiveness,
or budget impact, of specific treatment interventions. Details
of the methods and results of the studies are presented in
Table 5. Three studies were from the UK [25, 26, 98], while
the remaining were from France [99], Greece [100], Italy
[101, 102], Spain [103], Mexico [104] and USA [105]. The
comparators included triple therapy (azathioprine, NAC and
steroids), a combination of triple therapy and a genotypic
assay thiopurine S-methyltransferase (TPMT), co-trimoxa-
zole, sildenafil, pirfenidone, nintedanib and best supportive
care. Only one economic evaluation included lung trans-
plantation as an option for patients [26].
Most studies used a model to synthesise clinical,
HRQoL and cost evidence. Moreover, the majority of the
analyses used the direct healthcare perspective. Wilson
et al. [98] conducted an economic evaluation alongside a
multi-centre, randomised, placebo-controlled, double-blind
trial of 12 months duration, and reported cost-effectiveness
results on both the healthcare direct medical and societal
perspectives.
In the economic models, the time horizon ranged
between 1, 5 and 30 years, and patient lifetime. A state
transition model was used for all papers, and when repor-
ted, results were calculated by a cohort analysis. In the long
time-horizon models, the cost results varied between
US$4000 (£3000) for BSC, US$7000 for NAC and over
US$90,000 for new treatments such as pirfenidone and
nintedanib. HRQoL benefits ranged between 3 and 4
QALYs. There was a noticeable distinction in the cost
effectiveness of old pharmacologic technologies such as
triple therapy or NAC, with estimates between US$5000–
US$70,000 per QALY, and that of new treatments that
exceeded US$100,000 per QALY.
Table 2 continued
Study Patient characteristics HRQoL multi-
attribute
measurement tool
IPF utility score Population
reference dataa
Fell et al. [12] Details were not reported (abstract) HUI2 1st year: 0.585
4th year: 0.432
USA population,
age
65–74 years:
0.85
DLCO diffusing capacity of the lungs for carbon monoxide, EQ-5D EuroQol 5-level, FVC forced vital capacity, HRQoL health-related quality of
life, HUI2 Health Utilities Index Mark 2, IPF idiopathic pulmonary fibrosis, N/A not available, VAS Visual Analogue Scale
aEQ-5D index population norms (country-specific time trade-off value sets) [78, 79]
bThe study used the EQ-5D-5L version, which may not be directly comparable to the population reference data
Fig. 4 EuroQol 5-level
questionnaire (EQ-5D) in
patients with idiopathic
pulmonary fibrosis (IPF)
compared with the general
population (reference). FVC
forced vital capacity. Asterisk
indicates data from by Rinciog
et al. were available by FVC%
predicted status. The lowest and
highest of the available intervals
are shown in the figure [25]
A. Diamantopoulos et al.
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4 Discussion
This was a review of HRQoL, resource use, costs and
treatment cost-effectiveness studies conducted over the last
20 years in many countries, and with a variety of objec-
tives, sources of data, and methodologies. As such, it is
difficult to express with one coherent estimate the burden
of illness of IPF. Nevertheless, several trends appeared in
both quality of life and costs.
As with other respiratory conditions, the impact of IPF
is not only limited to a worsening of the patient’s breathing
function. It has wider consequences for HRQoL including
physical (body weight loss, fatigue, clubbing) and social
ones (recreational activities, relationships etc.). When
reviewing the HRQoL evidence, this review reported on
most instruments used in the literature, but focused on
generic preference-based measures (such as EQ-5D) to
quantify the burden of the disease. By using EQ-5D it is
possible to make a comparison between the HRQoL levels
with the condition versus the general population, and a
comparison across other non-respiratory diseases. Fur-
thermore, EQ-5D is increasingly used in health economic
evaluations to calculate quality-adjusted life-years
(QALYs), and this work presents a comprehensive review
of the available evidence.
Despite the regional differences, there was some
agreement between study estimates on the absolute level of
HRQoL for patients with IPF; in EQ-5D, scores varied
between 0.67 (± 0.242) [67] and 0.8 (± 0.2) [106]. To put
this in context, the EQ-5D of patients with arthritis/
rheumatism/fibrositis was reported to be 0.597 (CI
0.584–0.609; N = 4145), with hypertension/high blood
pressure 0.777 (CI 0.765–0.788; N = 3172) and with
asthma 0.797 (CI 0.779–0.814; N = 2452) [107, 108]. In
the studies analysed, the decrement in HRQoL for patients
with IPF compared with the reference population statistics
was between 0.1 and 0.2 points in the EQ-5D.
With regards to costs, three US studies produced com-
parable estimates of costs per patient around US$20,000
[41, 42, 44]. After adjustments for the study years and
currency, the suggested annual per capita cost of IPF
patients in North America was estimated between 2.5–3.5
times the national health care expenditure.
We observed discrepancy in the estimates coming from
two Spanish studies. This is probably attributed to the
methods used. Pedraza-Serrano et al. [97] used data from a
Spanish National Hospital Database (CMBD, Conjunto
Mı´nimo Ba´sico de Datos) and conducted a retrospective,
descriptive, epidemiological study. Morell et al. [91] took a
different approach by synthesising expert opinion from 15
clinicians with unit costs from national formularies.
Moreover, Morell et al. [91] included treatments costs,
although treatment allocation was not reported. The two
estimates are very different to values from the other
countries (in absolute and relative terms), which makes it
very challenging to select the most accurate. The study by
Pedraza-Serrano et al. [97] follows the general trend of a
higher per annum cost than the national health expenditure.
Among the cost evidence identified in the literature, we
emphasised the existence of matched control cohort studies
[41, 42, 93]. These papers provided a direct comparison of
the excess costs and resource use of IPF patients versus a
Table 4 Cost burden of IPF
Study Cost
year
Currency IPF annual cost per patient (USD conversion for
study year)
National per capita health
expenditure
IPF/
NHE
Collard et al. [42] NR USD $26,378 USA 2012: $8423 3.13
Collard et al. [41, 153] 2012 USD One year before index quarter: $10,124
One year after: $20,887
USA 2012: $8423 2.48
Hill et al. [88] NR GBP £1414a ($2259) UK 2014: $3989 0.57
Kim et al. [63, 156] NR USD $1376–$1744 Korea 2016: $2729 0.64
Mittmann et al. [94] 2014 CAD $19,421± $18,961 ($17,444± $17,031) Canada 2014: $4502 3.87
Morell et al. [91] 2013 EUR €26,435.1 ($35,373) Spain 2013: $2941 12.03
Pedraza-Serrano et al.
[97]
NR EUR €5249.35± €7737.83 ($5584± $8232) Spain 2016: $3248 1.72
Raimundo et al.
[44, 159]
2011 USD $21,732b USA 2011: $8145 2.67
CAD Canadian Dollars, EUR Euros, GBP Great British Pounds, IPF idiopathic pulmonary fibrosis, NHE national per capita health expenditure,
NR not reported, USD US Dollars
aEstimated annual cost of service provisions in England. No treatment costs were included
b36.6% of $59,379 per patient in 2011
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reference population. Given that these studies were large in
sample size and from a contemporary (2012 and 2015) and
generalisable database, they produced relevant estimates
for the cost burden of illness of IPF. Therefore, we rec-
ommend the use of control or reference cohorts when
conducting cost analyses as it provides the relevant
benchmark for comparison with the general population.
Two studies also suggested a strong correlation between
acute exacerbations of IPF and other external conditions
such as seasonality. Collard et al. [41] reported that acute
exacerbations of IPF become more frequent in spring and
winter. Kim et al. [63] highlighted spring as the season
with most events, and linked that to the yellow dust phe-
nomena occurring during that period in Korea, where this
study was conducted.
The reader should note the relevance of national
guidelines and prescription rules when comparing costs
from different countries. Countries with a single (public)
payer system, like the UK, have different practices and
prescription rules to multiple-payer systems such as Ger-
many in Europe or the US. It is also relevant to consider
that some countries may have delayed access to new
treatments; for instance, Australia only gained access to
new anti-fibrotic agents in 2017, while Europe and the US
has had access since 2010–2015.
The evidence on treatment economic evaluations was
sparser. The cross-comparison of cost-effectiveness
analyses is often hindered by different methodologies,
time horizons, approaches in the presentation of the
results and many other factors. On this occasion, an
additional challenge was that most studies were published
only as conference abstracts and, as such, provided little
information on their methods and results. This made any
comparison or synthesis of cost-effectiveness estimates
very difficult.
One omission of our cost estimates is related to the
diagnosis of IPF. The diagnostic procedures are largely in
common with other ILDs and in most diagnostic cost
studies evidence was presented from a heterogenous cohort
that included patients with IPF as a subgroup [87, 109]. To
include only studies that had an IPF subgroup may have
been a misrepresentation of the actual management costs.
For internal consistency with our population criteria, we
decided to keep the reference database specific to IPF and
excluded diagnostic cost studies from our review.
Our qualitative comparison of HRQoL and cost esti-
mates with population reference statistics has further lim-
itations. The synthesis of evidence from various studies
involved the comparison of different EQ-5D versions (3L
vs 5L) and conversions of cost estimates to one currency.
This required several assumptions about the comparability
of the data.
This review excluded relevant conference proceedings
(published only as abstracts) before 2015. Records pub-
lished since 2015 were included. Although the information
from an abstract is often limited and the research lacks the
scrutiny of an academic journal, we considered it important
to include more recent records that report relevant infor-
mation and that could later be published as full manu-
scripts. This improves the comprehensiveness of the
records presented in this review.
However, the inclusion of abstracts could bias the syn-
thesised data used to estimate the burden of illness. For
instance, in the HRQoL studies we included data from the
INSIGHTS-IPF registry [80–84] and Fell et al. [12] that at
the time were available only as abstracts. In the cost studies
we included Hill et al. [88] and Mittmann et al. [94].
In our search for evidence on the burden of IPF, we
identified other similar literature reviews. Loveman et al.
[26] conducted a systematic review with the objective
being the comparison of the clinical effectiveness and cost
effectiveness of IPF treatment interventions. Our study was
not searching specifically for treatment effects, although
there was a lot of overlap in our searches for HRQoL and
economic evaluations; we identified the same papers in
HRQoL and economic evaluations as Loveman et al. In
addition, we have used Loveman et al. to validate our
review findings [26] within the overlapping time periods.4
Lee et al. [6] reported on the unmet public health need
with IPF. Although they cover quality of life and resource
utilisation, their analysis on the burden of the disease was
focused more around the epidemiology, comorbidities and
symptoms of IPF.
The treatment of IPF has changed substantially in recent
years, and has evolved a lot since the first paper identified
in our search was published (2000). We identified an
exponential growth of publications in the last 3–5 years.
This trend probably follows the development of new
pharmacological interventions such as pirfenidone and
nintedanib. For instance, we identified many publications
referring to results from three nintedanib clinical trials—
TOMORROW, INPULSIS I and II [25, 110–121].
With the exception of the evidence reported in the cost-
effectiveness studies, our review did not capture the full
effect of new treatments in IPF. As the pipeline of available
treatments expands, new research will be added to the
existing data. We recommend a timely update of this
review to capture the influx of new studies and any con-
temporary research. This will be crucial when informing
policy decisions in diagnosis, treatment and palliation of
patients with IPF.
4 Some studies included in Loveman et al., not available in the
English language, were not selected in our review, given our protocol
inclusion criteria.
Idiopathic Pulmonary Fibrosis Burden of Illness
5 Conclusion
IPF is a chronic, debilitating condition affecting a growing
proportion of the population; predominantly male and the
elderly. Our review found evidence of an important health
burden of the disease in comparison with HRQoL levels of
the general population. Furthermore, our review high-
lighted an excess cost and resource use for healthcare
providers. This confirms IPF as a growing threat for public
health worldwide with considerable impact on both
patients and healthcare providers.
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